Game Plan Financial Advisors LLC Sells 2,120 Shares of Pfizer Inc. (NYSE:PFE)

Game Plan Financial Advisors LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 68.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 980 shares of the biopharmaceutical company’s stock after selling 2,120 shares during the quarter. Game Plan Financial Advisors LLC’s holdings in Pfizer were worth $27,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. D.A. Davidson & CO. grew its position in Pfizer by 35.1% in the 2nd quarter. D.A. Davidson & CO. now owns 1,571,090 shares of the biopharmaceutical company’s stock worth $43,959,000 after purchasing an additional 408,234 shares during the last quarter. Privium Fund Management B.V. lifted its stake in shares of Pfizer by 23.9% in the second quarter. Privium Fund Management B.V. now owns 36,120 shares of the biopharmaceutical company’s stock valued at $1,005,000 after buying an additional 6,960 shares during the period. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the second quarter worth about $126,000. Drive Wealth Management LLC increased its stake in Pfizer by 31.4% during the second quarter. Drive Wealth Management LLC now owns 20,596 shares of the biopharmaceutical company’s stock valued at $576,000 after acquiring an additional 4,925 shares during the period. Finally, Massachusetts Wealth Management raised its holdings in Pfizer by 35.3% in the 2nd quarter. Massachusetts Wealth Management now owns 71,432 shares of the biopharmaceutical company’s stock valued at $1,999,000 after acquiring an additional 18,650 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, August 19th. Finally, UBS Group upped their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

Shares of PFE traded up $0.29 during mid-day trading on Friday, hitting $29.01. 37,137,599 shares of the company traded hands, compared to its average volume of 26,838,326. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $164.39 billion, a price-to-earnings ratio of -483.42, a PEG ratio of 1.02 and a beta of 0.69. The business has a 50-day moving average of $28.99 and a 200 day moving average of $28.01. Pfizer Inc. has a one year low of $25.20 and a one year high of $36.29.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $0.67 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.79%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.